Theriva Biologics (NYSEAMERICAN:TOVX) Shares Up 2.6% – Here’s What Happened

Shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) rose 2.6% during trading on Tuesday . The company traded as high as $0.2472 and last traded at $0.2401. Approximately 962,701 shares were traded during trading, a decline of 64% from the average session volume of 2,703,499 shares. The stock had previously closed at $0.2340.

Wall Street Analysts Forecast Growth

Separately, Maxim Group upgraded shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $1.00.

Theriva Biologics Price Performance

The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $7.71 million, a P/E ratio of -0.01 and a beta of 1.09. The stock has a 50 day moving average of $0.28 and a 200-day moving average of $0.24.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $0.30 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC boosted its stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,087 shares of the company’s stock after buying an additional 183,878 shares during the quarter. Geode Capital Management LLC owned approximately 0.63% of Theriva Biologics worth $45,000 as of its most recent SEC filing. 6.17% of the stock is currently owned by institutional investors and hedge funds.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.